Title

Cardiovascular Health Status of Childhood Cancer Survivors Treated With Anthracyclines

Presenter

Morrow Toomey

Abstract

Anthracycline-based anticancer drugs pose a unique challenge to researchers seeking to improve long-term health outcomes in pediatric cancer patients as these drugs are associated with superior treatment outcomes, as well as late-cardiotoxic events. In adult cancer patients, the cardioprotectant dexrazoxane (DRZ) has been shown to mitigate associated cardiotoxicity when given in conjunction with anthracycline-based agents. In children, studies of the efficacy of dexrazoxane have been more limited. In order to better understand the effects of DRZ, individuals who were treated from 1996-2001 on Children’s Oncology Group DRZ randomized clinical trials were approached for prospective health assessment at sites across North America. Eligible survivors were assessed on anthropometry, six-minute walk distance, and self-reported physical activity and smoking history. Our analysis compared these data across DRZ treatment arms and compared survivors to an age-matched general population sample to give a preliminary cardiovascular health update on childhood cancer survivors treated with anthracyclines.

Faculty Sponsor

James Russo

Sponsor Department/Programs

Anthropology

Tracks

Poster Session

Terms of Use

If you have questions about permitted uses of this content, please contact the ARMINDA administrator

Location

Cordiner Hall

Presentation Type

Poster

Research Funding Source or OCS Program

the Whitman-FHCRC Summer Internship Fund, the Cancer Center Support Grant CURE Supplement, the FHCRC?€?s Internship Program, and individual FHCRC groups

This document is currently not available here.

Share

COinS
 
Apr 19th, 1:00 PM Apr 19th, 2:00 PM

Cardiovascular Health Status of Childhood Cancer Survivors Treated With Anthracyclines

Cordiner Hall

Anthracycline-based anticancer drugs pose a unique challenge to researchers seeking to improve long-term health outcomes in pediatric cancer patients as these drugs are associated with superior treatment outcomes, as well as late-cardiotoxic events. In adult cancer patients, the cardioprotectant dexrazoxane (DRZ) has been shown to mitigate associated cardiotoxicity when given in conjunction with anthracycline-based agents. In children, studies of the efficacy of dexrazoxane have been more limited. In order to better understand the effects of DRZ, individuals who were treated from 1996-2001 on Children’s Oncology Group DRZ randomized clinical trials were approached for prospective health assessment at sites across North America. Eligible survivors were assessed on anthropometry, six-minute walk distance, and self-reported physical activity and smoking history. Our analysis compared these data across DRZ treatment arms and compared survivors to an age-matched general population sample to give a preliminary cardiovascular health update on childhood cancer survivors treated with anthracyclines.

Rights Statement

Rights Statement

In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).